<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916160</url>
  </required_header>
  <id_info>
    <org_study_id>UF 9703</org_study_id>
    <nct_id>NCT02916160</nct_id>
  </id_info>
  <brief_title>Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study</brief_title>
  <acronym>ENTRESTO696</acronym>
  <official_title>Evaluation in Real Life Conditions of Sacubitril-valsartan Combination in Patients With Chronic Heart Failure and Sleep Apnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Heart Failure (CHF) is a frequent pathology burdened with mortality and significant&#xD;
      morbidity. Sleep apnea syndrome (SAS) is frequently associated with CHF in 20% to 75% of&#xD;
      cases. Treatment of SAS is however inconsistently associated with a decline in the morbidity&#xD;
      and mortality. To date, the CHF medical treatments have been reported to be inconsistently&#xD;
      efficient in the treatment of SAS.&#xD;
&#xD;
      SACUBITRIL-VALSARTAN (ENTRESTO®) is a new treatment of CHF recently indicated class I, level&#xD;
      B in the recent European Society of Cardiology (ESC) guidelines 2016 on CHF. PARADIGM-HF&#xD;
      trial demonstrated that morbidity and mortality can be improved with SACUBITRIL-VALSARTAN. In&#xD;
      comparison to enalapril, it reduced the occurrence of cardiovascular death or hospitalisation&#xD;
      for CHF by 20% with a 16% reduction in all-cause mortality.&#xD;
&#xD;
      The purpose of the research is the evaluation of SACUBITRIL-VALSARTAN combination in CHF&#xD;
      patients presenting sleep apnea syndrome. A three months real life observational trial is&#xD;
      performed. A measure of the Apnea Hypopnea Index is realised before and after 3 months of&#xD;
      SACUBITRIL-VALSARTAN treatment. A concomitant evaluation of cardiological and quality of life&#xD;
      parameters is realized.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Chronic Heart Failure (CHF) is a frequent pathology burdened with mortality and&#xD;
      significant morbidity. Chronic HF provides almost 2% of health expenditure in developed&#xD;
      countries, it is the largest expenditure item in the USA (34.8 billion dollars). In most&#xD;
      developed countries, including France, mortality 1 year after diagnosis of chronic HF is 40%,&#xD;
      it is 50% at 2 years, and over 70% at 4.5 years.&#xD;
&#xD;
      Sleep apnea syndrome (SAS) is frequently associated with HF in 20% to 75% of cases. The&#xD;
      presence of an apnea syndrome is associated with a greater morbidity and mortality. Treatment&#xD;
      of SAS is however inconsistently associated with a decline in the morbidity and mortality. To&#xD;
      date, the CHF medical treatments have been reported to be inconsistently efficient in the&#xD;
      treatment of SAS : 6 studies corresponding to a total of 67 patients and 5 types of molecules&#xD;
      reported an incomplete effect on the central component of the Apnea Hypopnea Index (AHI) for&#xD;
      these patients.&#xD;
&#xD;
      SACUBITRIL - VALSARTAN (ENTRESTO®) is a new treatment of HF recently indicated class I, level&#xD;
      B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and&#xD;
      valsartan. After initial failures with neprilysin inhibition alone or dual&#xD;
      neprilysin-angiotensin converting enzyme (ACE) inhibition, the PARADIGM-HF trial demonstrated&#xD;
      that morbidity and mortality can be improved with the SACUBITRIL - VALSARTAN combination&#xD;
      (formerly LCZ696). In comparison to the ACE inhibitor enalapril, sacubitril/valsartan reduced&#xD;
      the occurrence of the primary end point (cardiovascular death or hospitalisation for HF) by&#xD;
      20% with a 16% reduction in all-cause mortality. These findings suggest that&#xD;
      sacubitril/valsartan should replace an ACE inhibitor or angiotensin receptor blocker as the&#xD;
      foundation of treatment of symptomatic patients (NYHA II-IV) with HF and a reduced ejection&#xD;
      fraction.&#xD;
&#xD;
      The purpose of the research is the evaluation of SACUBITRIL-VALSARTAN in CHF patients&#xD;
      presenting sleep apnea syndrome. We speculate that synchronously of a beneficial effect on&#xD;
      heart failure, the SACUBITRIL-VALSARTAN combination could improve an associated SAS and in&#xD;
      particular the central component of the AHI index.&#xD;
&#xD;
      After an exhaustive initial pre-therapeutic evaluation, the SACUBITRIL-VALSARTAN combination&#xD;
      treatment is initiated for 3 months.&#xD;
&#xD;
      The pre-therapeutic evaluation includes cardiological and biological exams, quality of life&#xD;
      questionaries and nocturnal ventilatory polygraphy.&#xD;
&#xD;
      Considering the results of the polygraphy, three groups of patients are identified:&#xD;
&#xD;
        -  group 1 patients, characterized by a central AHI ≥5 / h and an obstructive AHI &lt;15 / h,&#xD;
&#xD;
        -  group 2 patients, characterized by an obstructive AHI ≥15 / h whatever is the central&#xD;
           component. In this group of patient, a ventilator treatment with constant positive&#xD;
           airway pressure or auto-servoventilation is started.&#xD;
&#xD;
        -  group 3 patients, characterized by a central AHI &lt; 5 / h and an obstructive AHI &lt;15 / h.&#xD;
&#xD;
      After three months of treatment, the final evaluation includes cardiological and biological&#xD;
      exams, quality of life questionaries for all the patient included in the trial. A nocturnal&#xD;
      polygraphy is performed only in group 1 and 2 patients. For group 2 patients treated with a&#xD;
      device, the observance to the device, the residual AHI device and the pressure device is&#xD;
      measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2016</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Apnea-Hypopnea Index as compared to baseline</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Changes in AHI as compared to baseline Measure of the apnea hypopnea index by a polygraphy performed before and after 3 months of treatment. The 2012 American Academy of Sleep Medicine recommendations are utilized in order to characterized apnea and hypopnea events, the central or obstructive or mixed phenotype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Global Assessment</measure>
    <time_frame>0 month to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>0 month to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rhythm</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>physiological parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic Blood Pressure</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>physiological parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function as compared to baseline (Estimated GFR (eGFR) will be calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>CKD-EPI formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP (B-type Natriuretic Peptide) rates</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Biological parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject medications</measure>
    <time_frame>0 month to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Minnesota Living with Heart Failure Questionary</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Questionaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by EQ-5D-3L Questionary</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Questionaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Questionary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pichot Fatigue Scale</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Questionary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of device used in group 2 patients</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>CPAP or ASV device CPAP/ASV : continuous positive airway pressure / adaptive servo ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPAP/ASV compliance in group 2 patients</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>CPAP/ASV compliance. Unit : number of hour per day using CPAP/ASV device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Historical of CPAP/ASV compliance in group 2 patients</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>CPAP/ASV compliance. Unit : number of day with ≥3 hours in the past 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Settings of CPAP/ASV device used in group 2 patients</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Settings of device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of mask used in group 2 patients</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Type of mask</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Historical use of mask in group 2 patients</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Historical use of mask</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in AHI compared to Baseline in group 2 patients</measure>
    <time_frame>0 month to 3 months</time_frame>
    <description>Changes in AHI compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>SACUBITRIL - VALSARTAN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)</intervention_name>
    <description>SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.</description>
    <arm_group_label>SACUBITRIL - VALSARTAN</arm_group_label>
    <other_name>LCZ696, ENTRESTO®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age is greater than or equal to 18 years&#xD;
&#xD;
          -  Patient with chronic heart failure (LVEF ≤ 45%).&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal insufficiency (GF&lt;30 milliliters/min)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Allergy to one compound&#xD;
&#xD;
          -  Personal history of angiooedema&#xD;
&#xD;
          -  Hemodynamical instability&#xD;
&#xD;
          -  Severe hepatopathy&#xD;
&#xD;
          -  Current and not treated hyperkaliemia&#xD;
&#xD;
          -  Prognosis &lt; 6months&#xD;
&#xD;
          -  Current CPAP or ASV treatment for Sleep Apnea Syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud BOURDIN, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle médical spécialisé MSP</name>
      <address>
        <city>Béziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Béziers</name>
      <address>
        <city>Béziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Jaffuel D, Molinari N, Berdague P, Pathak A, Galinier M, Dupuis M, Ricci JE, Mallet JP, Bourdin A, Roubille F. Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design. ESC Heart Fail. 2018 Jun;5(3):222-230. doi: 10.1002/ehf2.12270. Epub 2018 Feb 22.</citation>
    <PMID>29469206</PMID>
  </reference>
  <results_reference>
    <citation>Jaffuel D, Nogue E, Berdague P, Galinier M, Fournier P, Dupuis M, Georger F, Cadars MP, Ricci JE, Plouvier N, Picard F, Puel V, Mallet JP, Suehs CM, Molinari N, Bourdin A, Roubille F. Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study. ESC Heart Fail. 2021 Aug;8(4):2513-2526. doi: 10.1002/ehf2.13455. Epub 2021 Jun 8.</citation>
    <PMID>34102018</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart failure</keyword>
  <keyword>Sleep Apnea Syndrome</keyword>
  <keyword>Continuous Positive Airways Pressure</keyword>
  <keyword>SACUBITRIL - VALSARTAN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

